Latest News and Press Releases

BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a...

Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14.

QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammationQUANTRO CEO Dr. Michael Bauer to...

Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.

CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...

VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in...

CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco.

New life science partnering conference to debut that prepares and helps industry dealmakers and stakeholders for the JP Morgan Healthcare Conference week

BioNTech rechnet mit zehn oder mehr laufenden potenziell zulassungsrelevanten Studien bis Ende 2024Der Aufbau kommerzieller Kapazitäten zur Vorbereitung auf Produkteinführungen soll Ende 2025...